2025-05-23-Jefferies-奥特勒斯治疗公司（AUTL）_ASCO25AucatzyI在各年龄组中显示出一致的疗效_安全性_7页_104kb

Autolus Therapeutics received a "Buy" equity rating with a 12-month price target of $12.00, representing a significant upside from the current price of $1.53. The key focus of this analysis is on the CAR-T therapy Obe-cel for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), highlighted by data from the FELIX trial presented at ASCO'25.

The post-hoc analysis showed consistent efficacy and safety across age groups (<55 vs. ≥55 years). The overall response rate (ORR) was 88% in patients aged ≥55 years and 72% in those <55 years, with minimal remission rates similar at 84% and 83.3%, respectively, achieved by month 3. Event-free survival (EFS) was slightly higher for younger patients (14 months vs. 12 months), and durable remission at one year was 68% and 52% for <55 and ≥55 years. Importantly, safety profiles were comparable, with low incidences of grade 3+ CRS and ICANS, supporting wider clinical adoption despite slight variations; for instance, treatment-related mortality was 0% in younger patients versus 4.2% in older ones.

The deep molecular remission responses observed with Obe-cel may predict better survival outcomes and could reduce healthcare costs, as fewer patients in the <55 group proceeded to stem cell transplants (30% vs. 2%). This data underscores Obe-cel's potential as a bridging therapy.

Beyond B-ALL, Obe-cel demonstrated encouraging efficacy in lupus nephritis, with a 50% complete response rate in severe cases, showing promise in a multi-billion dollar autoimmune market. Ongoing Phase 1 trials for progressive multiple sclerosis and AL amyloidosis are expected to start dosing by year-end 2025, further advancing the pipeline.

Autolus is a biopharmaceutical company based in London, spun out from University College London in 2014, developing five clinical-stage CAR-T therapies for hematological and solid tumors. However, risks include clinical, manufacturing, competitive, regulatory, and commercial challenges, which could impact valuation.

The high upside potential is rooted in Obe-cel's compelling data, strong market differentiation, and pipeline expansions, positioning Autolus as an attractive investment opportunity.